Proteostasis Therapeutics Inc

NASDAQ:PTI  
1.61
-0.06 (-3.59%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)81.95M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.13 Million
Adjusted EPS-$0.21
See more estimates
10-Day MA$1.66
50-Day MA$1.41
200-Day MA$1.45
See more pivots

PROTEOSTASIS THERAPEUTICS, INC. Stock, NASDAQ:PTI

200 TECHNOLOGY SQUARE, CAMBRIDGE, MA 02139
India
Phone: 617-225-0096
Number of Employees: 48

Description

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.